Effects of Dexmedetomidine Combined with Remifentanil Anesthesia and Propofol Combined with Remifentanil Anesthesia on Perioperative Inflammatory Response and Pulmonary Function in Patients with Lung Cancer

To explore the effects of dexmedetomidine combined with remifentanil anesthesia and propofol combined with remifentanil anesthesia on perioperative inflammatory response and pulmonary function in patients with lung cancer. Totally 128 patients admitted to our hospital for lung cancer surgery were taken as the research object of this experiment. Among them, 67 cases were sedated with dexmedetomidine combined with remifentanil (Group A), and 61 cases were sedated with propofol combined with remifentanil (Group B). The changes of vital signs, respiratory interval (RR), blood oxygen saturation (SpO2) and blood sugar before and after sedation were recorded. The changes of inflammatory factors TNF-α, IL-6, IL-10, pulmonary function indexes FEV1, FVC, FEV1/FVC in the two groups at 24 hours after sedation were observed. Hemodynamic heart rate (HR), mean arterial pressure (MAP) and other indexes before and after sedation were observed. VAS pain score and MMSE score before and after sedation were compared between the two groups. The incidence of adverse reactions after sedation was observed in the two groups. The decrease of RR and SpO2 in Group B was more remarkable than that in Group A (p < 0.05). The elevation of blood sugar in Group A was lower than that in Group B (p < 0.05). Group A had lower levels of TNF-α and IL-6 and higher level of IL-10 (p < 0.05), and higher expression of FEV1, FVC and FEV1/FVC when compared with Group B (p < 0.05). The decrease of HR and MAP in Group B was greater than that in Group A (p < 0.05). VAS score was lower in Group A than Group B (p < 0.05), and MMSE score was higher in Group A than Group B (p < 0.05). The incidence of adverse reactions in Group A was lower than that in Group B, p < 0.05. Compared with propofol, dexmedetomidine combined with remifentanil anesthesia is more effective in improving postoperative inflammatory factors and pulmonary function of lung cancer patients, which is worthier of recommendation.